Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2009

View Archived Issues

Snapshots: Recent studies of Novexel's oral streptogramin NXL-103

Advanced Life Sciences reports results from primate study of plague antibiotic Restanza

Updated results on cediranib in advanced cancers reported

Pantoprazole sodium identified as independent risk factor for nosocomial pneumonia

NB-201 attenuates infection/inflammation in a rat partial thickness burn injury model

BI-2536 shows limited or no antitumor activity in advanced solid tumors

Phase I data presented on MKC-253 in healthy subjects and type 2 diabetes patients

Amicus Therapeutics plans to initiate phase I AT-2220 study for Pompe disease

Wyeth initiates phase II trial in TNF-alpha Nanobody collaboration with Ablynx

Plethora Solutions reports results from studies of PSD-506 for overactive bladder

DOR BioPharma changes its name to Soligenix

BioCryst presents update on peramivir for influenza in the U.S.

Merck KGaA submits NDA to FDA for cladribine in relapsing forms of multiple sclerosis

Catalyst to continue development of vigabatrin for cocaine and methamphetamine addiction

Welichem Biotech files CTA for phase II trial of WBI-1001 in atopic dermatitis

Sanofi pasteur reports results from trial of influenza A (H1N1) monovalent vaccine

HRA Pharma launches ellaOne emergency contraception in Europe

Phenomenome Discoveries to begin trials on its diagnostic test and drug for AD

ImmunoCellular Therapeutics reports results from pilot study of antibody candidate ICT-109

U.S. Navy awards contract to Vical to develop pandemic influenza vaccine

Comparable HbA1c reduction seen with INT-131 and pioglitazone in type 2 diabetes

Meridian Bioscience and Buhlmann Laboratories sign distribution agreement for Quantum Blue

Adenosine A1 agonists disclosed by Bayer Schering Pharma

Novel monoamine transport inhibitors described by Roche for depression and anxiety

Novel Aurora-A kinase inhibitors identified by Banyu for cancer treatment

Provectus begins open-label phase I trial of PV-10 in liver cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...